Larimar Therapeutics, Inc.
US ˙ NasdaqGM ˙ US5171251003

SecurityLRMR / Larimar Therapeutics, Inc.
InstitutionBarclays Plc
Latest Disclosed Ownership78,470 shares
Latest Disclosed Value $ 298,971
Barclays Plc reports 10.69% increase in ownership of LRMR / Larimar Therapeutics, Inc.

On February 13, 2026 - Barclays Plc filed a 13F-HR form disclosing ownership of 78,470 shares of Larimar Therapeutics, Inc. (US:LRMR) valued at $298,971 USD as of December 31, 2025. The entity filed a previous 13F-HR/A on March 31, 2026 disclosing 70,893 shares of Larimar Therapeutics, Inc.. This represents a change in shares of 10.69% during the quarter. The current value of the position is $251,104 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F LARIMAR THERAPEUTICS COM 517125100 78,470 7,577 10.69 299 30.70 0.0001
2026-03-31 2025-09-30 13F/A-3 LARIMAR THERAPEUTICS COM 517125100 70,893 -13,967 -16.46 229 -6.94 0.0000
2026-03-19 2025-09-30 13F/A-2 LARIMAR THERAPEUTICS COM 517125100 60,032 -24,828 393 0.0001
2025-11-12 2025-09-30 13F LARIMAR THERAPEUTICS COM 517125100 70,893 -13,967 229 0.0000
2026-02-27 2025-06-30 13F/A-2 LARIMAR THERAPEUTICS COM 517125100 84,860 30,601 56.40 245 111.21 0.0001
2025-08-14 2025-06-30 13F/A-1 LARIMAR THERAPEUTICS COM 517125100 84,860 30,601 0 0.0001
2025-08-13 2025-06-30 13F LARIMAR THERAPEUTICS COM 517125100 84,860 30,601 0 0.0000
2026-03-17 2025-03-31 13F/A-1 LARIMAR THERAPEUTICS COM 517125100 54,259 -16,166 -22.95 117 -57.35 0.0000
2025-05-15 2025-03-31 13F LARIMAR THERAPEUTICS COM 517125100 54,259 -16,166 0 0.0000
2026-03-19 2024-12-31 13F/A-1 LARIMAR THERAPEUTICS COM 517125100 70,425 10,393 17.31 273 -30.79 0.0001
2025-02-13 2024-12-31 13F LARIMAR THERAPEUTICS COM 517125100 70,425 10,393 0 0.0001
2026-03-31 2024-09-30 13F/A-2 LARIMAR THERAPEUTICS COM 517125100 60,032 45,781 321.25 393 281.55 0.0001
2024-11-19 2024-09-30 13F/A-1 LARIMAR THERAPEUTICS COM 517125100 60,032 45,781 0 0.0001
2024-11-15 2024-09-30 13F LARIMAR THERAPEUTICS COM 517125100 60,032 45,781 0 0.0000
2026-03-23 2024-06-30 13F/A-1 LARIMAR THERAPEUTICS COM 517125100 14,251 -3,953 -21.72 103 -25.36 0.0000
2024-08-14 2024-06-30 13F LARIMAR THERAPEUTICS COM 517125100 14,251 -3,953 0 0.0000
2026-03-24 2024-03-31 13F/A-1 LARIMAR THERAPEUTICS COM 517125100 18,204 -17,087 -48.42 138 -13.75 0.0000
2024-05-15 2024-03-31 13F LARIMAR THERAPEUTICS COM 517125100 18,204 -17,087 0 0.0000
2026-03-25 2023-12-31 13F/A-1 LARIMAR THERAPEUTICS COM 517125100 35,291 30,261 601.61 161 742.11 0.0001
2024-02-15 2023-12-31 13F LARIMAR THERAPEUTICS COM 517125100 35,291 30,261 0 0.0001
2026-03-26 2023-09-30 13F/A-1 LARIMAR THERAPEUTICS COM 517125100 5,030 -49,202 -90.73 20 -88.76 0.0000
2023-11-07 2023-09-30 13F LARIMAR THERAPEUTICS COM 517125100 5,030 -49,202 0 0.0000
2026-03-30 2023-06-30 13F/A-2 LARIMAR THERAPEUTICS COM 517125100 54,232 25,939 91.68 170 32.03 0.0001
2023-09-20 2023-06-30 13F/A-1 LARIMAR THERAPEUTICS COM 517125100 54,232 25,939 0 0.0001
2023-08-03 2023-06-30 13F LARIMAR THERAPEUTICS COM 517125100 54,232 25,939 0 0.0001
2026-03-30 2023-03-31 13F/A-1 LARIMAR THERAPEUTICS COM 517125100 28,293 28,293 128 0.0001
2023-05-04 2023-03-31 13F LARIMAR THERAPEUTICS COM 517125100 28,293 28,293 0 0.0001
2020-05-13 2020-03-31 13F ZAFGEN COM 98885E103 0 -236 -100.00 0 0.0000
2020-02-10 2019-12-31 13F ZAFGEN COM 98885E103 236 -435 -64.83 0 0.0000
2019-11-15 2019-09-30 13F/A-1 ZAFGEN COM 98885E103 671 231 52.50 0 -100.00
2019-11-14 2019-09-30 13F ZAFGEN COM 98885E103 671 231 0 0.0000
2019-08-14 2019-06-30 13F ZAFGEN COM 98885E103 440 -8,575 -95.12 1 -96.00 0.0000
2019-05-15 2019-03-31 13F ZAFGEN COM 98885E103 9,015 7,192 394.51 25 177.78 0.0000
2019-02-14 2018-12-31 13F ZAFGEN COM 98885E103 1,823 -9,614 -84.06 9 -93.28 0.0000
2018-11-14 2018-09-30 13F ZAFGEN COM 98885E103 11,437 9,746 576.35 134 688.24 0.0001
2018-08-14 2018-06-30 13F ZAFGEN COM 98885E103 1,691 -19,187 -91.90 17 -89.03 0.0000
2018-05-15 2018-03-31 13F ZAFGEN COM 98885E103 20,878 20,863 139,086.67 155 0.0001
2018-02-14 2017-12-31 13F ZAFGEN COM 98885E103 15 0 0.00 0 0.0000
2017-11-14 2017-09-30 13F ZAFGEN COM 98885E103 15 -61,054 -99.98 0 -100.00
2017-08-14 2017-06-30 13F ZAFGEN COM 98885E103 61,069 49,130 411.51 214 282.14 0.0002
2017-05-15 2017-03-31 13F ZAFGEN COM 98885E103 11,939 5,413 82.95 56 180.00 0.0001
2017-02-14 2016-12-31 13F ZAFGEN COM 98885E103 6,526 6,383 4,463.64 20 0.0000
2016-11-14 2016-09-30 13F ZAFGEN COM 98885E103 143 -199 -58.19 0 -100.00
2016-08-12 2016-06-30 13F ZAFGEN COM 98885E103 342 200 140.85 2 100.00 0.0000
2016-05-16 2016-03-31 13F ZAFGEN COM 98885E103 142 -8,407 -98.34 1 -98.08 0.0000
2016-02-12 2015-12-31 13F ZAFGEN COM 98885E103 8,549 1,229 16.79 52 -77.09 0.0001
2015-11-13 2015-09-30 13F ZAFGEN COM 98885E103 7,320 6,950 1,878.38 227 1,646.15 0.0003
2015-08-14 2015-06-30 13F ZAFGEN COM 98885E103 370 -212 -36.43 13 -40.91 0.0000
2015-05-19 2015-03-31 13F/A-1 ZAFGEN COM 98885E103 582 22 3.93 22 29.41 0.0000
2015-05-14 2015-03-31 13F ZAFGEN COM 98885E103 582 22
2015-02-13 2014-12-31 13F ZAFGEN COM 98885E103 560 560 17 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.